A nitric oxide‐releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure
Open Access
- 20 January 2004
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 18 (3) , 587-588
- https://doi.org/10.1096/fj.03-0872fje
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- The therapeutic potential of NO‐NSAIDsFundamental & Clinical Pharmacology, 2003
- Pharmacology and potential therapeutic applications of nitric oxide‐releasing non‐steroidal anti‐inflammatory and related nitric oxide‐donating drugsBritish Journal of Pharmacology, 2002
- Vascular dysfunction and heart failure: Epiphenomenon or etiologic agent?American Heart Journal, 2002
- Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamstersAmerican Journal of Physiology-Heart and Circulatory Physiology, 2000
- Progressive Cardiac Dysfunction and Fibrosis in the Cardiomyopathic Hamster and Effects of Growth Hormone and Angiotensin-Converting Enzyme InhibitionCirculation, 1999
- Interactions among ACE, kinins and NOCardiovascular Research, 1999
- Endothelial Dysfunction: From Physiology to TherapyJournal of Molecular and Cellular Cardiology, 1999
- Angiotensin-Converting Enzyme InhibitorsCirculation, 1998
- Effects of Enalapril on the Collagen Matrix in Cardiomyopathic Syrian Hamsters (BIO 14.6 and 53.58)Japanese Circulation Journal, 1996
- Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure.Circulation, 1980